PHARMACOLOGY OA WGU D116
COMPLETELY SOLVED
drug cycle - ANSWERabsorption, distribution, metabolism, excretion
absorption - ANSWERmedication absorbed in GI mucosa.
what effects absorption rate - ANSWERfat, pH, concentration of medication, length of
contact, age, food, depth of breathing
distribution - ANSWERmedication transported via circulatory system to point of action
metabolism - ANSWERmedication metabolized by liver
excretion - ANSWERdrug removed from body so they don't build up
US pharmacopia - ANSWERcreated in 1820, where first listed drug standards
controlled substance act of 1970 - ANSWERrequired hospitals to register with DEA
NCC MERP A - ANSWERno error, capacity to cause error
NCC MERP B - ANSWERerror that didn't reach the patient
NCC MERP C - ANSWERerror that reached patient but unlikely to cause harm
NCC MERP D - ANSWERerror that reached the patient, could have necessitated
monitoring and/or intervention to preclude harm
NCC MERP E - ANSWERerror that could have caused temporary harm
NCC MERP F - ANSWERerror that could have caused temporary harm requiring initial,
prolonged hospitalization
NCC MERP G - ANSWERerror that could have resulted in permanent harm
NCC MERP H - ANSWERerror that could have necessitated intervention to sustain life
NCC MERP I - ANSWERerror that could have resulted in death
FDA pregnancy risk A - ANSWERlowest, studies have not shown a risk to mother, fetus
FDA pregnancy risk B - ANSWERslight, animal studies haven't shown risk to fetus,
human studies have not
, FDA pregnancy risk C - ANSWERmoderate, animal studies have shown risk to fetus,
controlled studies not performed on women
FDA pregnancy risk D - ANSWERrisky, studies shows drugs may harm fetus, may use
if another safer therapy is unavailable
FDA pregnancy risk X - ANSWERhighest, studies shown significant risk to mother, fetus
when is the fetus vulnerable to medication - ANSWERfirst, third trimester
schedule I drugs - ANSWERhigh, not accepted medical use in US
schedule II drugs - ANSWERhigh, may lead to severe dependence, no refills unless a
written perscription
schedule III drugs - ANSWERless than drugs, substances in schedule I/II, may lead to
moderate dependence, high psychological dependence
refill 5 times within 6 months
schedule IV drugs - ANSWERlow relative to substances in schedule III, may lead to
limited dependence. phone, fax of prescription allowed
schedule V drugs - ANSWERlow, relative to substances in schedule IV, may lead to
limited dependence
class I recall - ANSWERdangerous drug, defective product could cause serious health
problems, death
class II recall - ANSWERproduct might cause temporary health problem, pose slight
threat of serious nature
class III recall - ANSWERproduct that's unlikely to cause any adverse health reaction,
but violates FDA labeling, manufacturing laws
phase I clinical trials - ANSWERdetermine safety, few healthy participants take drug for
several months to measure any harmful events
phase II clinical trials - ANSWERmain goals of these trails is to see whether a drug
works as desired
phase III clinical trials - ANSWERdrugs that have been proven to be safe, effective.
conducted in hospitals, offices, clinics, testing for safety, effectiveness, dosage,
therapeutic does
phase IV clinical trials - ANSWERpost marketing, uses thousands of clients
COMPLETELY SOLVED
drug cycle - ANSWERabsorption, distribution, metabolism, excretion
absorption - ANSWERmedication absorbed in GI mucosa.
what effects absorption rate - ANSWERfat, pH, concentration of medication, length of
contact, age, food, depth of breathing
distribution - ANSWERmedication transported via circulatory system to point of action
metabolism - ANSWERmedication metabolized by liver
excretion - ANSWERdrug removed from body so they don't build up
US pharmacopia - ANSWERcreated in 1820, where first listed drug standards
controlled substance act of 1970 - ANSWERrequired hospitals to register with DEA
NCC MERP A - ANSWERno error, capacity to cause error
NCC MERP B - ANSWERerror that didn't reach the patient
NCC MERP C - ANSWERerror that reached patient but unlikely to cause harm
NCC MERP D - ANSWERerror that reached the patient, could have necessitated
monitoring and/or intervention to preclude harm
NCC MERP E - ANSWERerror that could have caused temporary harm
NCC MERP F - ANSWERerror that could have caused temporary harm requiring initial,
prolonged hospitalization
NCC MERP G - ANSWERerror that could have resulted in permanent harm
NCC MERP H - ANSWERerror that could have necessitated intervention to sustain life
NCC MERP I - ANSWERerror that could have resulted in death
FDA pregnancy risk A - ANSWERlowest, studies have not shown a risk to mother, fetus
FDA pregnancy risk B - ANSWERslight, animal studies haven't shown risk to fetus,
human studies have not
, FDA pregnancy risk C - ANSWERmoderate, animal studies have shown risk to fetus,
controlled studies not performed on women
FDA pregnancy risk D - ANSWERrisky, studies shows drugs may harm fetus, may use
if another safer therapy is unavailable
FDA pregnancy risk X - ANSWERhighest, studies shown significant risk to mother, fetus
when is the fetus vulnerable to medication - ANSWERfirst, third trimester
schedule I drugs - ANSWERhigh, not accepted medical use in US
schedule II drugs - ANSWERhigh, may lead to severe dependence, no refills unless a
written perscription
schedule III drugs - ANSWERless than drugs, substances in schedule I/II, may lead to
moderate dependence, high psychological dependence
refill 5 times within 6 months
schedule IV drugs - ANSWERlow relative to substances in schedule III, may lead to
limited dependence. phone, fax of prescription allowed
schedule V drugs - ANSWERlow, relative to substances in schedule IV, may lead to
limited dependence
class I recall - ANSWERdangerous drug, defective product could cause serious health
problems, death
class II recall - ANSWERproduct might cause temporary health problem, pose slight
threat of serious nature
class III recall - ANSWERproduct that's unlikely to cause any adverse health reaction,
but violates FDA labeling, manufacturing laws
phase I clinical trials - ANSWERdetermine safety, few healthy participants take drug for
several months to measure any harmful events
phase II clinical trials - ANSWERmain goals of these trails is to see whether a drug
works as desired
phase III clinical trials - ANSWERdrugs that have been proven to be safe, effective.
conducted in hospitals, offices, clinics, testing for safety, effectiveness, dosage,
therapeutic does
phase IV clinical trials - ANSWERpost marketing, uses thousands of clients
